Pembrolizumab Plus Lu-177-PSMA-617 in Patients with Castration Resistant Prostate Cancer

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu-177 Dotatate) for Pancreatic Neuroendocrine Tumors

Lu-177-DOTA-EB-TATE in Adult Patients with Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer

A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants with Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

Radiation Medication (Radium-223 Dichloride) versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

An Open-label Phase 3 Study of Lutetium (Lu-177) Oxodotreotide Injection in Subjects with Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

A Phase Ib/II Open-label Study of AMO959 with Lutetium (Lu-177) Vipivotide Tetraxetan (AAA617) in Combination with ARPI in Adult Participants with PSMA-positive mCRPC

Lu-177-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) with Bone Marrow Involvement and Cytopenia

Scout Dose of Resin Microspheres (LASER)

Open-label Study Comparing AAA817 versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [Lu-177]Lu-PSMA Targeted Therapy (PSMAcTION)